About Evecxia Therapeutics
Evecxia Therapeutics is a company based in Durham (United States) founded in 2013 by Marc Caron and Jacob Jacobsen. Evecxia Therapeutics has raised $14.85 million across 3 funding rounds. Evecxia Therapeutics offers products and services including 5-HTP-based Drugs. Evecxia Therapeutics operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
- Headquarter Durham, United States
- Founders Marc Caron, Jacob Jacobsen
- SectorsHealthcare
- Email••••••••
- Website evecxia.com
- Legal Name Evecxia Therapeutics, Inc.
- Total Equity Funding$14.85M (USD)
in 3 rounds
- Latest Funding Round$5M (USD), Series A
Sep 2025
Products & Services of Evecxia Therapeutics
Evecxia Therapeutics offers a comprehensive portfolio of products and services, including 5-HTP-based Drugs.
Amplifies serotonin production to treat mental illnesses effectively.
Funding Insights of Evecxia Therapeutics
Evecxia Therapeutics has successfully raised a total of $14.85M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.85M
- Total Rounds 3
- Last Round Series A — $5M
- First Round $7.41M
(Sep 2020)
All 3 funding rounds of Evecxia Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2025 | $5M | Series A | – | – | – |
| Sep 2023 | $2.44M | Series A | – | – | – |
| Sep 2020 | $7.41M | Series A | – | – | – |
People of Evecxia Therapeutics
4 people are tracked at Evecxia Therapeutics (4 in leadership).
| Name | Role | Group |
|---|---|---|
Marc Caron | Co-Founder | Leadership |
Jacob Jacobsen | Co-Founder | Leadership |
John Kaiser | CEO | Leadership |
Joseph M. Patti | CEO | Leadership |
Complete people profiles for Evecxia Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Evecxia Therapeutics
3 dated milestones of Evecxia Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Evecxia Therapeutics is founded.
- Funding First funding round of $7.4M.
- Funding Latest funding round, Series A, of $5.0M.
Competitors of Evecxia Therapeutics
Evecxia Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| supernus.com | 2005 | Rockville, United States | – | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | |
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| pasithea.com | 2020 | Miami Beach, United States | $1.46M | 15 | Pasithea is focused on developing treatments for neurological disorders. | |
| synchroneuron.com | 2006 | Newton, United States | $26M | – | Improved acamprosate formulations are developed for neuropsychiatric disorders. | |
| naurex.com | 2008 | Evanston, United States | $162.11M | – | Novel therapies for depression and CNS disorders are developed clinically. | |
| cadenttx.com | 2010 | Cambridge, United States | $63.73M | 13 | Precision medicines for neurological diseases are developed by Cadent Therapeutics. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. |
Detailed competitors of Evecxia Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Evecxia Therapeutics
The website of Evecxia Therapeutics (evecxia.com) receives about 3K visits a month.
- Monthly visits3K
▲ 92.3% vs previous month
Latest news on Evecxia Therapeutics
Complete news archive for Evecxia Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Evecxia Therapeutics
10 companies that operate in the same segment as Evecxia Therapeutics (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Evecxia Therapeutics
Evecxia Therapeutics was founded in 2013 and raised its 1st funding round 7 years after it was founded.
Evecxia Therapeutics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
John Kaiser is the current CEO of Evecxia Therapeutics.
Evecxia Therapeutics is a funded company, having raised a total of $14.85M across 3 funding rounds to date. The company's 1st funding round was a Series A of $7.41M, raised on Sep 2020.
Evecxia Therapeutics was founded in 2013 and is based in Durham, United States. Focus is placed on the development of therapies targeting central nervous system disorders within the biotechnology sector. Operations center on advancing pharmaceutical candidates, including the lead product EVX-101 for neuropsychiatric conditions. This reformulated therapy incorporates low-dose carbidopa and 5-hydroxytryptophan to serve as an adjunctive antidepressant, supporting enhanced efficacy of SSRI and SNRI treatments.
Evecxia Therapeutics's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
Evecxia Therapeutics offers 5-HTP-based Drugs.
Evecxia Therapeutics operates through Evecxia Therapeutics, Inc..